콘텐츠로 건너뛰기
Merck
모든 사진(5)

주요 문서

P1138

Sigma-Aldrich

1,2-Distearoyl-sn-glycero-3-phosphocholine

≥99%

동의어(들):

PC, 1,2-Dioctadecanoyl-sn-glycero-3-phosphocholine, 3-sn-Phosphatidylcholine, 1,2-distearoyl, L-α-Phosphatidylcholine, distearoyl, L-β,γ-Distearoyl-α-lecithin, DSPC, PC(18:0/18:0)

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C44H88NO8P
CAS Number:
Molecular Weight:
790.15
Beilstein:
3923978
EC Number:
MDL number:
UNSPSC 코드:
12352211
PubChem Substance ID:
NACRES:
NA.25

생물학적 소스

semisynthetic

Quality Level

분석

≥99%

양식

powder

작용기

phospholipid

지질 유형

phosphoglycerides

배송 상태

ambient

저장 온도

−20°C

SMILES string

[O-]P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O)=O

InChI

1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/t42-/m1/s1

InChI key

NRJAVPSFFCBXDT-HUESYALOSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

Non-pyrogenic, well-defined liposomes, loaded with a molecule of choice, are formed by a single hydration step.

애플리케이션


  • Amantadine interactions with phase separated lipid membranes.: This study explores the interactions between amantadine and phase-separated lipid membranes, providing insights into the role of 1,2-Distearoyl-sn-glycero-3-phosphocholine in membrane structure and function (Kinnun et al., 2024).

  • Design of charge converting lipid nanoparticles via a microfluidic coating technique.: This research designs lipid nanoparticles with charge-converting capabilities using 1,2-Distearoyl-sn-glycero-3-phosphocholine, enhancing drug delivery systems (Zöller et al., 2024).

  • Investigation and Comparison of Active and Passive Encapsulation Methods for Loading Proteins into Liposomes.: The study compares methods for protein encapsulation into liposomes using 1,2-Distearoyl-sn-glycero-3-phosphocholine, advancing drug delivery technologies (Pisani et al., 2023).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Sweta Modi et al.
Journal of controlled release : official journal of the Controlled Release Society, 162(2), 330-339 (2012-07-18)
Nanoparticulate drug carriers such as liposomal drug delivery systems are of considerable interest in cancer therapy because of their ability to passively accumulate in solid tumors. For liposomes to have practical utility for antitumor therapy in patients, however, optimization of
Peter J Kueffer et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(16), 6512-6517 (2013-03-29)
The application of boron neutron capture therapy (BNCT) following liposomal delivery of a (10)B-enriched polyhedral borane and a carborane against mouse mammary adenocarcinoma solid tumors was investigated. Unilamellar liposomes with a mean diameter of 134 nm or less, composed of
Pan Li et al.
Journal of controlled release : official journal of the Controlled Release Society, 162(2), 349-354 (2012-07-18)
Ultrasound targeted microbubble destruction (UTMD) was one of the most promising strategies to enhance drug delivery in cancer therapy. Microbubbles (MBs) serve as a vehicle to carry anti-tumor drugs and locally release them when exposed to therapeutic ultrasound, resulting in
Hyo-Kyung Han et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 46(5), 500-507 (2012-04-24)
This study aimed to design the chitosan coated liposomes of alendronate and optimize their in vitro/in vivo characteristics to improve the bioavailability as well as potentially to reduce the mucosal irritation of alendronate. Liposomes of alendronate were prepared with DSPC/DSPG
Saumyabrata Mazumder et al.
PLoS neglected tropical diseases, 5(12), e1429-e1429 (2011-12-30)
Vaccines that activate strong specific Th1-predominant immune responses are critically needed for many intracellular pathogens, including Leishmania. The requirement for sustained and efficient vaccination against leishmaniasis is to formulate the best combination of immunopotentiating adjuvant with the stable antigen (Ag)

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.